You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

OFS

Showing 1 - 25 of 52
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

To Observe and Evaluate the Clinical Efficacy and Safety of Continuous Use of OFS for Premenopausal Patients With Early Breast

Active, not recruiting
  • To Observe and Evaluate the Clinical Efficacy and Safety of Continuous Use of OFS for Premenopausal Patients With Early Breast Cancer After 5 Years
  • OFS continues to use group after 5 years
  • Immunohistochemical detection of HR status
  • Wuhan, Hubei, China
    Wu Xinhong
Sep 17, 2023

Breast Cancer Trial in Shanghai (OFS + Anastrozole, OFS + Exemestane)

Completed
  • Breast Cancer
  • OFS + Anastrozole
  • OFS + Exemestane
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022

Tension-Type Headache Episodic Trial (Osteo fluidic Sensitive méthod, Placebo method)

Recruiting
  • Tension-Type Headache Episodic
  • Osteo fluidic Sensitive méthod
  • Placebo method
  • Poitiers, France
    CHU Poitiers
Nov 29, 2022

Female Breast Cancer Trial in Germany

Recruiting
  • Female Breast Cancer
    • Moenchengladbach, NRW, Germany
    • +4 more
    Mar 30, 2023

    Breast Cancer Trial in Tianjin (Pyrrolidine?trastuzumab?AI)

    Recruiting
    • Breast Cancer
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Jun 1, 2023

    Breast Cancer Invasive Trial in Seoul (Leuplin or zoladex)

    Recruiting
    • Breast Cancer Invasive
    • Leuplin or zoladex
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Oct 16, 2022

    Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer Trial in Seoul (Ovarian function suppression with

    Not yet recruiting
    • Breast Cancer
    • +4 more
    • Ovarian function suppression with endocrine treatments
    • Seoul, Korea, Korea, Republic of
      Gangnam Severance Hospital
    Dec 18, 2022

    HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

    Recruiting
    • HR+/HER2- Advanced Breast Cancer
    • Targeted Therapy
    • Beijing, Beijing, China
      National Cancer Center/National Clinical Research Center for Can
    Aug 1, 2023

    RWE About QOL and Compliance of Patients With OFS in China

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • 3M GnRHa
    • 1M GnRHa
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Nov 15, 2021

    Non-alcoholic Fatty Liver Disease, Metabolic Syndrome Trial in Rechovot (ITF (Inulin/OFS 75/25), Placebo)

    Active, not recruiting
    • Non-alcoholic Fatty Liver Disease
    • Metabolic Syndrome
    • ITF (Inulin/OFS 75/25)
    • Placebo
    • Rechovot, Israel
      Kaplan Medical Center
    Sep 4, 2021

    Advanced HR+ HER2 Negative Breast Carcinoma Trial in Tianjin (Enituzumab injection+Abesili tablets+Anastrozole tablets)

    Recruiting
    • Advanced HR+ HER2 Negative Breast Carcinoma
    • Enituzumab injection+Abesili tablets+Anastrozole tablets
    • Tianjin, China
      Tianjin Cancer Hospital
    Apr 6, 2022

    Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian

    Not yet recruiting
    • Hormone-receptor-positive Breast Cancer
    • +3 more
    • Aromatase inhibitor
    • +3 more
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Apr 5, 2023

    CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective

    Recruiting
    • Breast Cancer
    • +2 more
      • Erlangen, Germany
        Department of Gynecology and Obstetrics, Erlangen University Hos
      May 12, 2023

      Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

      Not yet recruiting
      • Breast Cancer
      • +3 more
      • (no location specified)
      Aug 4, 2023

      Situation of Chinese County Population With Breast Cancer

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • pathological stage
      • Xinxiang, Henan, China
        The First Affiliated Hospital of Xinxiang Medical University
      Sep 13, 2022

      Metastatic Breast Cancer Trial in Johannesburg (Palbociclib, Exemestane, Goserelin)

      Recruiting
      • Metastatic Breast Cancer
      • Johannesburg, South Africa
        Wits Oncology center
      Jul 22, 2021

      HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

      Recruiting
      • HR Positive HER2 Negative Advanced Breast Cancer
      • Tianjin, China
        天津市肿瘤医院
      May 26, 2023

      Breast Cancer Trial in Worldwide (exemestane, tamoxifen, triptorelin)

      Active, not recruiting
      Has Results
      • Breast Cancer
      • Burbank, California
      • +227 more
      Nov 15, 2022

      Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma Trial in Canada,

      Active, not recruiting
      Has Results
      • Estrogen Receptor Positive Breast Cancer
      • +7 more
      • Birmingham, Alabama
      • +499 more
      Nov 15, 2022

      Quality of Life and Hormone Levels in Premenopausal Early Breast

      Recruiting
      • Early-stage Breast Cancer
        • Bologna, Italy
        • +17 more
        Jan 31, 2023

        Adenoid Vegetations in Adult Patients

        Recruiting
        • Adenoid Vegetation
          • Varazdin, Croatia
            Varazdin General Hospital
          Sep 16, 2023

          Patient Satisfaction Trial in Mansoura (Obturator)

          Active, not recruiting
          • Patient Satisfaction
          • Obturator
          • Mansoura, Egypt
            Mohammed ELSawy
          Oct 1, 2023

          Acute-On-Chronic Liver Failure In Cirrhotic Patients

          Completed
          • Cirrhosis, Liver
            • Sohag, Egypt
              Sohag University
            May 12, 2022

            Severe Acute Liver Disease Cases Admitted to Intensive Care

            Not yet recruiting
            • Acute Liver Disease
              • (no location specified)
              May 25, 2023

              Early-stage Breast Cancer Trial in Beijing, Langfang (The MRD strategy for high risk or MRD+ TNBC patients, The MRD strategy for

              Recruiting
              • Early-stage Breast Cancer
              • The MRD strategy for high risk or MRD+ TNBC patients
              • +5 more
              • Beijing, Beijing, China
              • +2 more
              Apr 21, 2022